Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland.
Department of Epidemiology and Biostatistics, Institute of Mother and Child, 01-211 Warsaw, Poland.
Cells. 2023 Mar 24;12(7):999. doi: 10.3390/cells12070999.
Resistin is a molecule that belongs to the Resistin-Like Molecules family (RELMs), the group of proteins taking part in inflammatory processes. Increased resistin concentrations are observed in cardiovascular complications. Resistin contributes to the onset of atherosclerosis and intensifies the atherosclerotic processes. The aim of this study was to investigate the relationship between resistin and cardiovascular (CV) risk in men with chronic kidney disease (CKD) not treated with dialysis.
One hundred and forty-two men were included in the study: 99 men with eGFR lower than 60 mL/min/1.73 m and 43 men with eGFR ≥ 60 mL/min/1.73 m. CV risk was assessed. Serum resistin, tumor necrosis factor-alpha (TNF-alpha) and plasminogen activator inhibitor-1 (PAI-1) were measured among other biochemical parameters.
We observed that resistin concentrations were significantly higher in patients with CKD compared to individuals with eGFR ≥ 60 mL/min/1.73 m ( = 0.003). In CKD, after estimating the general linear model (GLM), we found that resistin is associated with CV risk ( = 0.026) and PAI-1 serum concentrations (0.012). The relationship of PAI-1 with resistin depends on the level of CV risk in CKD ( = 0.048).
Resistin concentrations rise with the increase of CV risk in CKD patients and thus resistin may contribute to the progression of cardiovascular risk in this group of patients. The relationship between resistin and CV risk is modified by PAI-1 concentrations.
抵抗素是一种属于抵抗素样分子家族（RELMs）的分子，该蛋白家族参与炎症过程。心血管并发症患者的抵抗素浓度升高。抵抗素参与动脉粥样硬化的发生，并加剧动脉粥样硬化过程。本研究旨在探讨未接受透析治疗的慢性肾脏病（CKD）男性患者中抵抗素与心血管（CV）风险之间的关系。
本研究纳入了 142 名男性：99 名 eGFR 低于 60 mL/min/1.73 m，43 名 eGFR≥60 mL/min/1.73 m。评估 CV 风险。测量了血清抵抗素、肿瘤坏死因子-α（TNF-α）和纤溶酶原激活物抑制剂-1（PAI-1）等生化参数。
我们观察到 CKD 患者的抵抗素浓度明显高于 eGFR≥60 mL/min/1.73 m 的个体（ = 0.003）。在 CKD 中，在估计一般线性模型（GLM）后，我们发现抵抗素与 CV 风险（ = 0.026）和 PAI-1 血清浓度（0.012）相关。PAI-1 与抵抗素的关系取决于 CKD 中 CV 风险的水平（ = 0.048）。
CKD 患者的 CV 风险增加时，抵抗素浓度升高，因此抵抗素可能有助于该组患者心血管风险的进展。抵抗素与 CV 风险之间的关系受 PAI-1 浓度的调节。
